Pictilisib (GDC-0941)

Catalog No.S1065 Synonyms: RG7321

Molecular Weight(MW): 513.64

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Cited by 114 Publications

Nat Med, 2019, 25(5):838-849

PubMed: 31011202 ( click the link to review the publication )

Nat Med, 2018, 24(7):968-977

PubMed: 29808010 ( click the link to review the publication )

Cell, 2018, 172(1-2):373-386

PubMed: 29224780 ( click the link to review the publication )

J Clin Oncol, 2016, 34(8):794-802

PubMed: 26215952 ( click the link to review the publication )

Nature, 2014, 508(7494):118-22

PubMed: 24670642 ( click the link to review the publication )

Cancer Discov, 2012, 2(11):1036-47

PubMed: 22915752 ( click the link to review the publication )

Cell Stem Cell, 2012, 10(2):210-7

PubMed: 22305570 ( click the link to review the publication )

Cancer Discov, 2011, 1(7):608-25

PubMed: 22586683 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Cancer Res, 2019, 79(6):1138-1150

PubMed: 30679179 ( click the link to review the publication )

Cell Rep, 2019, 27(1):294-306

PubMed: 30943409 ( click the link to review the publication )

Cell Rep, 2019, 27(2):631-647

PubMed: 30970263 ( click the link to review the publication )

Int J Cancer, 2019, 145(3):817-829

PubMed: 30671946 ( click the link to review the publication )

Br J Pharmacol, 2019, 176(3):436-450

PubMed: 30427531 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):41

PubMed: 30691487 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):236

PubMed: 31164152 ( click the link to review the publication )

Cells, 2019, 8(2)

PubMed: 30795621 ( click the link to review the publication )

Mol Cancer Res, 2019, 10.1158/1541-7786.MCR-18-1332

PubMed: 31043489 ( click the link to review the publication )

Acta Pharmacol Sin, 2019, 40(5):677-688

PubMed: 30224636 ( click the link to review the publication )

Cancer Manag Res, 2019, 11:839-855

PubMed: 30697076 ( click the link to review the publication )

Cancer Biol Med, 2019, 16(1):66-83

PubMed: 31119047 ( click the link to review the publication )

Blood, 2018, 10.1182/blood-2018-08-872465

PubMed: 30322870 ( click the link to review the publication )

Cancer Res, 2018, 78(13):3645-3658

PubMed: 29760043 ( click the link to review the publication )

Cell Rep, 2018, 22(4):860-868

PubMed: 29420173 ( click the link to review the publication )
Oncogene, 2018, 37(10):1369-1385

PubMed: 29311642 ( click the link to review the publication )

EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Mol Cancer Res, 2018, 16(3):543-553

PubMed: 29222171 ( click the link to review the publication )

Int J Oncol, 2018, 52(3):828-840

PubMed: 29344641 ( click the link to review the publication )

Int J Oncol, 2018, 53(5):1881-1896

PubMed: 30132519 ( click the link to review the publication )

Proteomics, 2018, 18(23):e1800244

PubMed: 30267477 ( click the link to review the publication )

PLoS One, 2018, 13(5):e0193849

PubMed: 29799846 ( click the link to review the publication )

Anticancer Res, 2018, 38(11):6195-6200

PubMed: 30396937 ( click the link to review the publication )

Cell Host Microbe, 2017, 21(5):611-618

PubMed: 28494242 ( click the link to review the publication )

Mol Cell, 2017, 67(3):512-527

PubMed: 28757207 ( click the link to review the publication )

Clin Cancer Res, 2017, 23(18):5561-5572

PubMed: 28606920 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Cancer Res, 2017, 77(8):1892-1904

PubMed: 28108509 ( click the link to review the publication )

J Cell Biol, 2017, 216(6):1567-1577

PubMed: 28442534 ( click the link to review the publication )

Mol Cancer Ther, 2017, 10.1158/1535-7163.MCT-16-0415

PubMed: 28119489 ( click the link to review the publication )

Oncogenesis, 2017, 6(11):398

PubMed: 29184057 ( click the link to review the publication )

Biochem Biophys Res Commun, 2017, 489(1):14-20

PubMed: 28536078 ( click the link to review the publication )

Oncotarget, 2017, 8(32):52877-52888

PubMed: 28881779 ( click the link to review the publication )

J Thorac Oncol, 2016, 11(8):1345-1356

PubMed: 27117832 ( click the link to review the publication )

Leukemia, 2016, 30(9):1832-43

PubMed: 27174491 ( click the link to review the publication )

Elife, 2016, 10.7554/eLife.18489

PubMed: 27845624 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

PLoS One, 2016, 11(5):e0155230

PubMed: 27153109 ( click the link to review the publication )

Oncotarget, 2016, 7(8):9188-221

PubMed: 26802026 ( click the link to review the publication )
Nat Commun, 2015, 6:7212

PubMed: 25998442 ( click the link to review the publication )

Mol Syst Biol, 2015, 11(3):797

PubMed: 25814555 ( click the link to review the publication )

Int J Cancer, 2015, 10.1002/ijc.29579

PubMed: 25912635 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1591

PubMed: 25590801 ( click the link to review the publication )

Cell Death Dis, 2015, 6:e1711

PubMed: 25837487 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Exp Mol Med, 2015, 47:e143

PubMed: 25721419 ( click the link to review the publication )

Hum Mol Genet, 2015, 24(4):926-38

PubMed: 25292196 ( click the link to review the publication )

J Biol Chem, 2015, 290(40):24367-80

PubMed: 26294766 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: 25327687 ( click the link to review the publication )

Prostate, 2015, 75(3):242-54

PubMed: ( click the link to review the publication )

PLoS One, 2015, 10(9):e0133610

PubMed: 26402468 ( click the link to review the publication )

Oncotarget, 2015, 6(31):31792-804

PubMed: 26397139 ( click the link to review the publication )

Nat Struct Mol Biol, 2014, 21(6):522-7

PubMed: 24814346 ( click the link to review the publication )

Cancer Res, 2014, 10.1158/0008-5472.CAN-14-1392

PubMed: 25297634 ( click the link to review the publication )

Cancer Res, 2014, 74(17):4597-4611

PubMed: 25183785 ( click the link to review the publication )

Oncogene, 2014, 33(35):4418-23

PubMed: 24469055 ( click the link to review the publication )

Oncogene, 2014, 10.1038/onc.2014.328

PubMed: 25284585 ( click the link to review the publication )

Oncogene, 2014, 33(23):3043-53

PubMed: 23893244 ( click the link to review the publication )

Breast Cancer Res, 2014, 16(4):406

PubMed: 25103565 ( click the link to review the publication )

Pigment Cell Melanoma Res, 2014, 27(6):1154-8

PubMed: 25130256 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Pain, 2014, 155(6):1150-60

PubMed: 24631588 ( click the link to review the publication )

Gastric Cancer, 2014, 10.1007/s10120-014-0444-1

PubMed: 25407459 ( click the link to review the publication )
Neoplasia, 2014, 16(2):147-57

PubMed: 24709422 ( click the link to review the publication )

J Immunol, 2014, 193(6):3036-44

PubMed: 25092892 ( click the link to review the publication )

J Biol Chem, 2014, 289(33):22785-97

PubMed: 24982421 ( click the link to review the publication )

PLoS One, 2014, 9(9):e105919

PubMed: 25221930 ( click the link to review the publication )

PLoS One, 2014, 9(1):e84746

PubMed: 24404189 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 10.1016/j.bbrc.2014.09.129

PubMed: 25285632 ( click the link to review the publication )

Anticancer Drugs, 2014, 25(2):183-8

PubMed: 24100276 ( click the link to review the publication )

Harvard University, 2014,

PubMed: ( click the link to review the publication )

Blood, 2013, 121(12):2274-84

PubMed: 23341541 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(20):5749-57

PubMed: 23948972 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(9):2584-91

PubMed: 23515407 ( click the link to review the publication )

Clin Cancer Res, 2013, 19(19):5413-22

PubMed: 23888070 ( click the link to review the publication )

Leukemia, 2013, 27(11):2118-28

PubMed: 23535559 ( click the link to review the publication )

Cell Death Differ, 2013, 21(3):491-502

PubMed: 24362439 ( click the link to review the publication )

Oncogene, 2013, 33(9):1190-7

PubMed: 23435426 ( click the link to review the publication )

J Cell Sci, 2013, 126(Pt 5):1099-108

PubMed: 23345407 ( click the link to review the publication )

Cancer Sci, 2013, 104(8):1027-32

PubMed: 23710822 ( click the link to review the publication )

J Biol Chem, 2013, 288(21):14698-708

PubMed: 23585567 ( click the link to review the publication )

Cancer Med, 2013, 2(1):76-85

PubMed: 24133630 ( click the link to review the publication )

FEBS Lett, 2013, 587(1):5-16

PubMed: 23178716 ( click the link to review the publication )

PLoS One, 2013, 8(10):e77243

PubMed: 24130864 ( click the link to review the publication )

PLoS One, 2013, 8(6):e66306

PubMed: 23824914 ( click the link to review the publication )

Leuk Res, 2013, 38(1):109-15

PubMed: 23981382 ( click the link to review the publication )

J Surg Res, 2013, 184(2):898-906

PubMed: 23602735 ( click the link to review the publication )
Clin Cancer Res, 2012, 18(9):2502-14

PubMed: 22351686 ( click the link to review the publication )

Clin Cancer Res, 2012, 19(3):657-67

PubMed: 23251002 ( click the link to review the publication )

Proc Natl Acad Sci USA, 2012, 109(31):E2127-33

PubMed: 22773810 ( click the link to review the publication )

Eur J Cancer, 2012, 48(6):936-43

PubMed: 22088482 ( click the link to review the publication )

Cell Death Dis, 2012, 3:e400

PubMed: 23059819 ( click the link to review the publication )

J Cell Sci, 2012, 125(Pt 5):1259-73

PubMed: 22399812 ( click the link to review the publication )

Cancer Sci, 2012, 103(9):1665-71

PubMed: 22703543 ( click the link to review the publication )

Biochim Biophys Acta, 2012, 1823(12):2210-6

PubMed: 22974639 ( click the link to review the publication )

J Leukoc Biol, 2012, 92(1):219-31

PubMed: 22544939 ( click the link to review the publication )

Mol Cell Biol, 2012, 32(22):4674-83

PubMed: 22988297 ( click the link to review the publication )

PLoS One, 2012, 7(8):e44146

PubMed: 22952903 ( click the link to review the publication )

PLoS One, 2012, 7(9):e46518

PubMed: 23029544 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(24):7595-604

PubMed: 22038996 ( click the link to review the publication )

Clin Cancer Res, 2011, 17(8):2260-9

PubMed: 21220474 ( click the link to review the publication )

P Natl Acad Sci USA, 2011, 108(37):E699-708

PubMed: 21876152 ( click the link to review the publication )

Cancer Res, 2011, 71(7):2750-60

PubMed: 21317224 ( click the link to review the publication )

J Invest Dermatol, 2011, 131(2):495-503

PubMed: 21048785 ( click the link to review the publication )

Sci Signal, 2011, 4(192):ra62

PubMed: 21954288 ( click the link to review the publication )

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Description

Pictilisib (GDC-0941) is a potent inhibitor of PI3Kα/δ with IC50 of 3 nM in cell-free assays, with modest selectivity against p110β (11-fold) and p110γ (25-fold). Phase 2.

Targets

p110α ^[1] (Cell-free assay)	p110δ ^[1] (Cell-free assay)	p110β ^[1] (Cell-free assay)	p110γ ^[1] (Cell-free assay)	mTOR ^[1] (Cell-free assay)
3 nM	3 nM	33 nM	75 nM	0.58 μM(Ki app)

In vitro

GDC-0941 is equipotent against PI3Kα and PI3Kδ as well as PI3Kα mutants E545-K and H1047-R, displaying modest levels of selectivity against PI3Kβ (10-fold) and PI3Kγ (25-fold), and greater levels of selectivity against members of PI3K class II, III, and IV, including C2β, Vps34, DNA-PK, and mTOR. GDC-0941 potently inhibits the phosphorylation of Akt in U87MG, PC3, and MDA-MB-361 cells with IC50 of 46 nM, 37 nM, and 28 nM, respectively. GDC-0941 inhibits the proliferation of U87MG, A2780, PC3, and MDA-MB-361 cells with IC50 of 0.95 μM, 0.14 μM, 0.28 μM, and 0.72 μM, respectively. ^[1] GDC-0941 treatment potently inhibits the proliferation of both trastuzumab-sensitive and -insensitive HER2-amplified cells with IC50 of 149-944 nM. GDC-0941 inhibits proliferation of HER2-amplified cells that harbor PIK3CA mutations with IC50 of <500 nM, and effectively inhibits both proliferation and viability of HER2-amplified breast cancer cells that are resistant to trastuzumab due to PTEN loss. ^[2] GDC-0941 significantly inhibits the growth of HCT116, DLD1 and HT29 cells with GI50 of 1081 nM, 1070 nM and 157 nM, respectively. ^[3] GDC-0941 inhibits tumor cell proliferation, induces apoptosis and suppresses centroblast population. ^[4]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Sf9	NHn4eFNMcW6jc3WgRZN{[Xl?		MXuxJIg>	MYLEUXNQ	MnS0TY5pcWKrdHnvckBw\iCqdX3hckBz\WOxbXLpcoFvfCCSSUPLJJAyOTCmZXz0ZUBmgHC{ZYPz[YQhcW5iU3[5JINmdGy\|IHPv[ZhxemW\|c3nu[{BxQDWjbIDoZUB4cXSqIFnDOVAhd2ZiMD6wNFMh\|ryP	NVvuSHF6OTh5NUS2OVQ>
Sf9	NFu0bIxMcW6jc3WgRZN{[Xl?		NG\iWZMyKGh?	M1qxbmROW09?	NV7MUmdLUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEhzMES3MXIhdXW2YX70JIV5eHKnc4Pl[EBqdiCVZkmgZ4VtdHNiY3;lfJBz\XO\|aX7nJJA5PWGucHjhJJdqfGhiSVO1NEBw\iByLkCwN{DPxE1?	NEHXZVQyQDd3NE[1OC=>
Sf9	MUfLbY5ie2ViQYPzZZk>		MYOxJIg>	NUXVTm5qTE2VTx?=	NWjXS3ZiUW6qaXLpeIlwdiCxZjDoeY1idiC{ZXPvcYJqdmGwdDDQTVNMKHBzMUDi[ZRiKEV3NEWtT{BufXSjboSg[ZhxemW\|c3XkJIlvKFOoOTDj[YxteyClb3X4dJJme3OrbnegdFg2[WyyaHGge4l1cCCLQ{WwJI9nKDBwMECzJO69VQ>?	NIjuR\|cyQDd3NE[1OC=>
Sf9	NHjRbVZMcW6jc3WgRZN{[Xl?		NX\YWIFHOSCq	M13UfGROW09?	NH\1U\|NKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHLleIEh\XiycnXzd4VlKGmwIGPmPUBk\WyuczDjc4V5eHKnc4PpcocheDh3YXzwbIEhf2m2aDDJR\|UxKG:oIECuNFM{KM7:TR?=	M3HBWlE5PzV2NkW0
Sf9	M4PpfGtqdmG\|ZTDBd5NigQ>?		NUnKR2lLOSCq	NGTFUm9FVVOR	NHe3XnpKdmirYnn0bY9vKG:oIHj1cYFvKHKnY3;tZolv[W62IGDJN2sheDFzMHHsdIhiKGW6cILld5Nm\CCrbjDT[lkh[2WubIOgZ49mgHC{ZYPzbY5oKHB6NXHsdIhi	Ml3WNVg4PTR4NUS=
MDA-MB-361	MnTpSpVv[3Srb36gRZN{[Xl?		MYWyJIg>	M1LSeWROW09?	NWH5XoJuUW6qaXLpeIlwdiCxZjDBb5QhW2W{NEezJJBpd3OyaH;yfYxifGmxbjDpckBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC5yMkig{txO	NHjiPXEyQDd3NE[1OC=>
PC3	M4PncWZ2dmO2aX;uJGF{e2G7		NHm5eY4zKGh?	NWW2XYtMTE2VTx?=	M3X2SWlvcGmkaYTpc44hd2ZiQXv0JHNmejR5MzDwbI9{eGixconsZZRqd25iaX6gVHRGVi2wdXzsJIh2dWGwIGDDN{Bk\WyuczD3bZRpKEmFNUCgc4YhOC5yM{eg{txO	NYD0RYJ2OTh5NUS2OVQ>
U87MG	NVXKS2VKTnWwY4Tpc44hSXO\|YYm=		MnzrNkBp	MYfEUXNQ	NG\iWGVKdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:wIHnuJHBVTU5vboXscEBpfW2jbjDVPFdOTyClZXzsd{B4cXSqIFnDOVAhd2ZiMD6wOFYh\|ryP	NHW0dXAyQDd3NE[1OC=>
MDA-MB-361	M1rRcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmXLPVYhcA>?	M1vSfmROW09?	NY[wbm1ISW62aYDyc4xq\mW{YYTpeoUh[WO2aY\peJkh[WejaX7zeEBpfW2jbjDNSGEuVUJvM{[xJINmdGy\|IIfpeIghWEmNM1PBJGU2PDVvSzDteZRifGmxbjD3bZRpKEmFNUCgc4YhOC55MjFOwG0>	NFLWNIwyQDd3NE[1OC=>
A2780	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NILKfVU6PiCq	NVPvXJd6TE2VTx?=	NF;TUlRCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFGyO\|gxKGOnbHzzJJdqfGhiUFnLN2NCKGGwZDDQWGVPKG23dHH0bY9vKHerdHigTWM2OCCxZjCwMlE1KM7:TR?=	NWnNcWdDOTh5NUS2OVQ>
PC3	Mlz4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NXvlSXo4QTZiaB?=	M1PhO2ROW09?	Ml\1TWM2OD1yLkK4JO69VQ>?	MmnLNVg4PTR4NUS=
U87MG	NYHQVo1vT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NF\wV\|A6PiCq	NW\ye3ZCTE2VTx?=	NHXv[HNKSzVyPUCuPVUh\|ryP	NUf2V\|d4OTh5NUS2OVQ>
Sf9	NHfoNodMcW6jc3WgRZN{[Xl?		NEPoboE{OCCvaX6=	MVXEUXNQ	MoXKTY5pcWKrdHnvckBw\iCqdX3hckBRUTONZ3HtcYEh\XiycnXzd4VlKGG\|c3Xzd4VlKGG\|IHHtc5VvfCCxZjDBWHAh[2:wc4Xt[YQhf2m2aDDJR\|UxKG:oIECuNFQzKM7:TR?=	NW[xeGlFOjJ3NEizOFI>
RAW 264.7	MmXnT4lv[XOnIFHzd4F6		M1XiZVkxKG2rbh?=	NYHMR2JyTE2VTx?=	MX\Jcohq[mm2aX;uJI9nKGi3bXHuJHBKO0upYX3tZUBmgHC{ZYPz[YQh[XO\|ZYPz[YQh[XNiaX7obYJqfGmxbjDv[kBCU1RicHjvd5Bpd3K7bHH0bY9vKHerdHigTWM2OCCxZjCwMlI6QCEQvF2=	MXyyNlU1QDN2Mh?=
Sf9	M4[yV2tqdmG\|ZTDBd5NigQ>?		NF\UXFIyKGh?		M3f1S2lvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tj\XSjIHX4dJJme3OnZDDpckBj[WO3bH;2bZJ2eyCrbn\lZ5Rm\CCVRkmgZ4VtdHNid3n0bEBKSzVyIH;mJFAvODF5IN88US=>	NUTN[nM{OjN3NEC2OFU>
Sf9	NFrV[4NMcW6jc3WgRZN{[Xl?		MXuxJIg>		M{[2[WlvcGmkaYTpc44hd2ZiR2PUMYZ2e2WmIHj1cYFvKHKnY3;tZolv[W62IGDJN2tl\Wy2YTDlfJBz\XO\|ZXS=	M3jCfVI{PTRyNkS1
Sf9	NV;I[Gp1U2mwYYPlJGF{e2G7		NYKwXlgzOSCq		NIq3T\|VKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM\2GvbXGg[ZhxemW\|c3Xk	NYHudFFoOjN3NEC2OFU>
Sf9	M4joTGtqdmG\|ZTDBd5NigQ>?		M3jyeVEhcA>?		NELEe\|NKdmirYnn0bY9vKG:oIFfTWE1nfXOnZDDoeY1idiC{ZXPvcYJqdmGwdDDQTVNM[WyyaHGg[ZhxemW\|c3Xk	MlrCNlM2PDB4NEW=
SKOV3	M4DEVWtqdmG\|ZTDBd5NigQ>?	MXixJO69VQ>?	M4SwcVEhcA>?	NYTmSmNZTE2VTx?=	NF2xPVZKdmirYnn0bY9vKG:oIGDJN2tidHCqYTDhd5Nme3OnZDDhd{BqdmirYnn0bY9vKG:oIFHreEBU\XJ2N{OgdIhwe3Cqb4L5cIF1cW:w	NWfJeVBWOjN\|NkCzOFg>
MCF7	NVzETVBET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NG[zUYwyKM7:TR?=	MmLSPVYhcA>?	MkSySG1UVw>?	MXrHTVUxRTBwMEewNkDPxE1?	MUSyN\|M3ODN2OB?=
SKOV3	NIX6fG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	M4m4ZVEh\|ryP	Mk\WPVYhcA>?	NYG2XlFUTE2VTx?=	NH3YbVBIUTVyPUCuNVQ4PiEQvF2=	NYHxZ3dUOjN\|NkCzOFg>
PC3	MkTBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NHX5cpg4OiCq	NXO1bY1kTE2VTx?=	NVrxNGxTUUN3ME2wMlI5KM7:TR?=	MYCyNVk5OTdzNB?=
MCF7.1	M3nXT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NHe4eng4OiCq	MljwSG1UVw>?	NGnxfG9CdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIF3DSlcvOSClZXzsd{BmgHC{ZYPzbY5oKEiHUkKg[4Vv\SC5aYToJGlEPTBib3[gNE4zQCEQvF2=	MkTjNlE6QDF5MUS=
MCF7-neo/Her2	M3S2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MmnFO\|IhcA>?	NYHKR\|I1TE2VTx?=	M2O3eWlEPTB;MD6yPUDPxE1?	NYjKNoJ7OjN4NkK5NFM>
MCF7-neo/Her2	NH7jTnRMcW6jc3WgRZN{[Xl?				MnnsTY5pcWKrdHnvckBw\iCSSUPLZYxxcGFiYYPz[ZN{\WRiYYOgdoVlfWO2aX;uJI9nKEGNVDDwbI9{eGixconsZZRqd25iYYSgV\|Q4OyC5aYToJGlEPTBib3[gNE4xODdizszN	M4O0S\|I{PjZ{OUCz
PC3	MkPWS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NVOwPIhnPzJiaB?=	MnzOSG1UVw>?	MXfFR\|UxRTBwM{Sg{txO	NVe0OlRXOjF7OEW2N\|k>
MCF7.1	M4PsSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		MkfnO\|IhcA>?	NGLoc5FFVVOR	M{nEV2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iTVPGO{4yKGOnbHzzJIV5eHKnc4PpcochWEl\|S3HsdIhiKG23dHHueEB4cXSqIFXDOVAhd2ZiMD6zPUDPxE1?	NGfU[HAzOTl6NU[zPS=>
PC3	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NXHwNnFnPzJiaB?=	Mn;tSG1UVw>?	Ml;DRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCSQ{OgZ4VtdHNiZHXmbYNq\W62IHnuJHBVTU5id3n0bEBKSzVyIH;mJFAvOzlizszN	MnnYNlAxPTB4Nkm=
MCF7.1	MkmxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M2HoeFczKGh?	MWDEUXNQ	MX3BcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKE2FRkeuNUBk\WyuczDlfJBz\XO\|aX7nJHBKO0ujbIDoZUBufXSjboSge4l1cCCLQ{WwJI9nKDBwM{Sg{txO	NVu4epI5OjByNUC2Olk>
MCF7.1	Mn;rS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		NEPyWpE4OiCq		MoDKSWM2OD1yLkeyJO69VQ>?	NH;HWlQzODN2Nk[1Oi=>
NCI-H1975	MV3DfZRwfG:6aXOgRZN{[Xl?		MX:3NkBp		M3nLV2lEPTB;MD6yO{DPxE1?	MXeyN\|A2QTV2NR?=
H460	MX7DfZRwfG:6aXOgRZN{[Xl?		MlvpO\|IhcA>?		NHHVOnJKSzVyPUCuPFch\|ryP	MnLoNlMxPTl3NEW=
HT-29	MUPDfZRwfG:6aXOgRZN{[Xl?		NFXjbmc4OiCq		NYnDUoZ1UUN3ME2wMlY3KM7:TR?=	Ml\uNlMxPTl3NEW=
HepG2	NIjheGVEgXSxdH;4bYMhSXO\|YYm=		MUe3NkBp		MofNTWM2OD1zIN88US=>	NVLJRWpROjNyNUm1OFU>
SGC7901	M1G1[2N6fG:2b4jpZ{BCe3OjeR?=		NFvLRnA4OiCq		NFjNeJJKSzVyPUGuPEDPxE1?	MXuyN\|A2QTV2NR?=
NCI-H226	MnPhR5l1d3SxeHnjJGF{e2G7		M3n3dlczKGh?		MXTJR\|UxRTJwOTFOwG0>	MoruNlMxPTl3NEW=
A549	MlHkR5l1d3SxeHnjJGF{e2G7		M3jLW\|czKGh?		MXXJR\|UxRTZwOTFOwG0>	NIPvd5EzOzB3OUW0OS=>
U87MG	M2\1VGN6fG:2b4jpZ{BCe3OjeR?=		NGD4Spo4OiCq		MkDYTWM2OD15Lke3JO69VQ>?	MWCyN\|A2QTV2NR?=
HBC4	NIP1RZRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M4LEVoxw\0eLNUC9MVYvODNiTR?=	NYPENXB{OjJ\|M{[yOFY>
BSY1	M{D0cGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2izcYxw\0eLNUC9MVYvQTBiTR?=	NWrHNpR[OjJ\|M{[yOFY>
HBC5	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrScI9oT0l3ME2tOk43OCCP	Mn35NlI{OzZ{NE[=
MCF7	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFH6VWFtd2eJSUWwQU04NjN\|IF2=	NYrrS3RtOjJ\|M{[yOFY>
MDA-MB-231	M4W4fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NX\RVY5xdG:pR1m1NF0uPS52NjDN	M4W1clIzOzN4MkS2
U251	NXe2SolGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4PrToxw\0eLNUC9MVUvPTBiTR?=	NXj2RYhYOjJ\|M{[yOFY>
SF268	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NUDvZnVudG:pR1m1NF0uPS5\|OTDN	NFXxdoozOjN\|NkK0Oi=>
SF295	M4TnOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MojVcI9oT0l3ME2tOk4{PyCP	MknsNlI{OzZ{NE[=
SF539	NYm1ZYZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MofNcI9oT0l3ME2tOk42OCCP	MmfrNlI{OzZ{NE[=
SNB75	M{Hvc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4jsSIxw\0eLNUC9MVcvOTBiTR?=	MYOyNlM{PjJ2Nh?=
SNB78	NITB[HZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVjsc4dIUTVyPT22MlUzKE1?	MnHkNlI{OzZ{NE[=
HCC2998	M4LJV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljJcI9oT0l3ME2tOk4zQSCP	M4nm[FIzOzN4MkS2
KM12	NXzqeYw3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTFcI9oT0l3ME2tOU44PiCP	NHPvbFgzOjN\|NkK0Oi=>
HT-29	NGHEco1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGPTW4xtd2eJSUWwQU03NjNyIF2=	NFzlSYczOjN\|NkK0Oi=>
HCT15	NF7reG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\Wd3Btd2eJSUWwQU03NjF{IF2=	MVSyNlM{PjJ2Nh?=
HCT116	NH;Le\|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlGzcI9oT0l3ME2tOU45PyCP	Mn;aNlI{OzZ{NE[=
NCI-H23	NVHINYRtT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWL0cnI{dG:pR1m1NF0uPS55MzDN	MYCyNlM{PjJ2Nh?=
NCI-H226	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGe2XoFtd2eJSUWwQU03NjJzIF2=	NXfvVFRSOjJ\|M{[yOFY>
NCI-H522	NUX6OmRbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlrPcI9oT0l3ME2tOk42QCCP	Mk\oNlI{OzZ{NE[=
NCI-H483	M4LKRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXzsc4dIUTVyPT22MlU3KE1?	NVPhW5dVOjJ\|M{[yOFY>
A549	NIHqe4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYXKNlZQdG:pR1m1NF0uPi5zNTDN	MofFNlI{OzZ{NE[=
DMS273	NEX1c\|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{GyNYxw\0eLNUC9MVYvPDNiTR?=	MkHUNlI{OzZ{NE[=
DMS114	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{\tdIxw\0eLNUC9MVUvQTJiTR?=	MmG2NlI{OzZ{NE[=
LOXIMVI	M3;q[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHLxboRtd2eJSUWwQU03NjJ7IF2=	M3Lyb\|IzOzN4MkS2
OVCAR3	NXnGVmc5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnCVW9TdG:pR1m1NF0uPi55MTDN	NFz2[ZMzOjN\|NkK0Oi=>
OVCAR4	M4Dyb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFPLfIZtd2eJSUWwQU02Njd4IF2=	NHm1eVAzOjN\|NkK0Oi=>
OVCAR5	MoriS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nNXYxw\0eLNUC9MVYvOjZiTR?=	M3TqVVIzOzN4MkS2
OVCAR8	M{T3W2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mmj4cI9oT0l3ME2tOU44OyCP	M{HONVIzOzN4MkS2
SKOV3	NX7zc3p4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGrjXFNtd2eJSUWwQU03NjV{IF2=	MU[yNlM{PjJ2Nh?=
RXF631L	NGTZcmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYPsc4dIUTVyPT22Mlg5KE1?	NG\Db5ozOjN\|NkK0Oi=>
ACHN	NXXFbmFYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1q5S4xw\0eLNUC9MVYvODdiTR?=	NUO4V4g6OjJ\|M{[yOFY>
St-4	NHnMOVlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HRXIxw\0eLNUC9MVUvPTZiTR?=	NEKxXXczOjN\|NkK0Oi=>
MKN1	MkT6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVPsc4dIUTVyPT23MlA5KE1?	M3rr[VIzOzN4MkS2
MKN7	M3fXO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUK0dogydG:pR1m1NF0uPi53MDDN	MojLNlI{OzZ{NE[=
MKN28	M1TISmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUTBRmFsdG:pR1m1NF0uPS53MjDN	MXKyNlM{PjJ2Nh?=
MKN45	NGjUSWFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MX7sc4dIUTVyPT22MlU2KE1?	M4Xyd\|IzOzN4MkS2
MKN74	NUPHSmd7T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVLsc4dIUTVyPT22MlAzKE1?	NFfjO4szOjN\|NkK0Oi=>
DU145	M{HVdGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmHZcI9oT0l3ME2tOU45PSCP	MWGyNlM{PjJ2Nh?=
PC3	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NH3lNlRtd2eJSUWwQU03NjZ4IF2=	NXPWOWVWOjJ\|M{[yOFY>
ES5	NXLWU2dWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFfzOWpKSzVyPUWwMlIyKG6P	M3vOZXNCVkeHUh?=
HH	NXPkPXIxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYPx[\|NGUUN3ME2xNVEvODhibl2=	MXvTRW5ITVJ?
MHH-PREB-1	MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVvJR\|UxRTFzND6zJI5O	M2GyT3NCVkeHUh?=
NCI-H1770	Mlr6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NI\Hc\|ZKSzVyPUGyN{45PiCwTR?=	NV6wbZQxW0GQR1XS
HuO9	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlOyTWM2OD1{ME[uNFIhdk1?	NF;rWZlUSU6JRWK=
HAL-01	NXnHcZNQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGroNIZKSzVyPUKwOk44OyCwTR?=	M{\wTHNCVkeHUh?=
NOS-1	Ml[0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NH\a[mVKSzVyPUKxNU45OiCwTR?=	M{TnRXNCVkeHUh?=
HGC-27	NGT5eIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXrJR\|UxRTJzMj61O{BvVQ>?	NVvtXms4W0GQR1XS
NB69	M2jqUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4n1WWlEPTB;MkS1MlI4KG6P	MkTtV2FPT0WU
RS4-11	M1zNbGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\tdWlEPTB;Mk[xMlc3KG6P	NV\Oe3EyW0GQR1XS
DOK	MmXOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYPJR\|UxRTNyMT63JI5O	M3jxTnNCVkeHUh?=
LB2241-RCC	Ml;wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MUTJR\|UxRTNyMz64OEBvVQ>?	M1TkN3NCVkeHUh?=
NCI-H1623	NE\oOGtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWP3U5NIUUN3ME2zNFQvODhibl2=	NGrw[4hUSU6JRWK=
YH-13	NV;Ud3hpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWnuem4zUUN3ME2zNFQvOzJibl2=	M{PYcnNCVkeHUh?=
BPH-1	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFTiVW5KSzVyPUOxOEBvVQ>?	NVzldY5zW0GQR1XS
AN3-CA	M{Ds[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{\GTGlEPTB;M{SwMlM4KG6P	M4XkPHNCVkeHUh?=
ES7	MkDrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYnNUIw1UUN3ME2zOFEvQTlibl2=	MkjYV2FPT0WU
MDA-MB-175-VII	NGTxflNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVzJR\|UxRTN3Mj65NkBvVQ>?	MWTTRW5ITVJ?
GAMG	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MofuTWM2OD1\|N{CuPFUhdk1?	MUfTRW5ITVJ?
CHL-1	NXnJUG1qT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2\qc2lEPTB;M{e4MlY2KG6P	NYroPGFGW0GQR1XS
NB7	M1jqOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFHhN4JKSzVyPUO4PU45OyCwTR?=	NEHCZ\|JUSU6JRWK=
MFE-280	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIrsTGNKSzVyPUSxPE4zKG6P	MlzEV2FPT0WU
HL-60	NEXnWoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MVfJR\|UxRTR{NT63OUBvVQ>?	NUD5PWo1W0GQR1XS
GCIY	NFvKNZVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIG2[VJKSzVyPUSzN{45KG6P	MXrTRW5ITVJ?
MDA-MB-361	NEHndXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HjUmlEPTB;NEO5MlE{KG6P	M{DRO3NCVkeHUh?=
LXF-289	Mn;MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWK4XVJqUUN3ME20OFgvOjdibl2=	M1fmSXNCVkeHUh?=
NBsusSR	NXnSXnhmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWPLSI92UUN3ME20PFgvQDVibl2=	NIDBZnNUSU6JRWK=
KU-19-19	NGLlPIlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mor2TWM2OD13MU[uNFchdk1?	NF7rdIhUSU6JRWK=
A204	M3rs[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGPYOZFKSzVyPUWyNk4{OyCwTR?=	MY\TRW5ITVJ?
LB1047-RCC	NEDTS\|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NX75fph5UUN3ME21NlIvQTNibl2=	MkHvV2FPT0WU
COLO-684	M4HrNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWru[2xRUUN3ME21NlMvOTFibl2=	MYXTRW5ITVJ?
PA-1	NIrIVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXPtNYQ{UUN3ME21N\|IvPDFibl2=	M{XuR3NCVkeHUh?=
MG-63	MnHMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGS5TllKSzVyPUW0NU4yOSCwTR?=	M4rtfXNCVkeHUh?=
BHT-101	NFfqTYNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUTqSmZvUUN3ME21OFQvQTRibl2=	M2Hh[XNCVkeHUh?=
NKM-1	MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHtTWM2OD13OUOuNFkhdk1?	NYjYellpW0GQR1XS
T47D	NInkcJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvyboFKSzVyPUW5O{42PiCwTR?=	M{L0e3NCVkeHUh?=
MOLT-4	MoTpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NF\4VolKSzVyPU[yN{43OiCwTR?=	M2OzUHNCVkeHUh?=
IGROV-1	Ml;US5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MY\JR\|UxRTZ\|ND6zNUBvVQ>?	NUGxTFk4W0GQR1XS
ES4	NETVSI9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYjJR\|UxRTZ\|OT61OEBvVQ>?	NFLoeHpUSU6JRWK=
HuO-3N1	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHPtenBKSzVyPU[0Nk4{QCCwTR?=	MXHTRW5ITVJ?
NEC8	Mn\2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmXsTWM2OD14NUOuOVchdk1?	NITKUmhUSU6JRWK=
HO-1-N-1	NGjOPWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXLVbYlkUUN3ME22OVkvOTdibl2=	MmTCV2FPT0WU
EPCL-272H	NWXZXoJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3jFVWlEPTB;Nki3MlIyKG6P	MXjTRW5ITVJ?
D-263MG	NEfEU4lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2TzeGlEPTB;N{G4MlEhdk1?	NGf4OoxUSU6JRWK=
MV-4-11	MkjaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWHVXWxJUUN3ME23NlQvOzFibl2=	NIjFd5VUSU6JRWK=
SK-NEP-1	NFXRbJVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUPnenNVUUN3ME23NlUvQTRibl2=	NFfKUI9USU6JRWK=
SW872	M1rVOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV7JR\|UxRTd{Nz64PUBvVQ>?	NE\kV\|lUSU6JRWK=
P30-OHK	NUDGT2g2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkfJTWM2OD15M{CuO\|Ehdk1?	NFzMfXRUSU6JRWK=
OMC-1	M4j3PGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYXLdmNQUUN3ME23OVEvODlibl2=	NXfCPZIyW0GQR1XS
LoVo	NVG3T5Q{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;ocGlEPTB;N{e3Mlkhdk1?	MUfTRW5ITVJ?
LNCaP-Clone-FGC	NFq2NINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mm[zTWM2OD15OU[uN\|Qhdk1?	MUXTRW5ITVJ?
L-363	M1rnV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTd7OD60NkBvVQ>?	M1rZUHNCVkeHUh?=
ES8	Mn\HS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NU\sTXA5UUN3ME24NVAvPTJibl2=	NVf5emYxW0GQR1XS
697	M4LyPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\hPGNWUUN3ME24N\|EvPTVibl2=	NET1TpdUSU6JRWK=
HSC-3	M1XRcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlHVTWM2OD16M{muOVQhdk1?	MmfyV2FPT0WU
H4	MnHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NV7GZXNuUUN3ME24OVAvQDVibl2=	M1fTT3NCVkeHUh?=
QIMR-WIL	NETqR4FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MonlTWM2OD16NkWuNkBvVQ>?	NEH5dW9USU6JRWK=
OAW-42	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M{HPd2lEPTB;OEeyMlE6KG6P	MkPQV2FPT0WU
MCF7	NHrpNmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn3OTWM2OD16OUiuOVkhdk1?	MU\TRW5ITVJ?
SCC-25	M4Lw[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2jtU2lEPTB;OUG0MlE6KG6P	MWHTRW5ITVJ?
NCI-H1563	M3\ndmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MlfqTWM2OD17MUWuPVkhdk1?	NXW3OmlXW0GQR1XS
OVCAR-5	NGnhRXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWTJR\|UxRTl2MD6xO{BvVQ>?	NFzVVGxUSU6JRWK=
HDLM-2	M3nOOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYqxNlVCUUN3ME25OFkvOiCwTR?=	M{TmN3NCVkeHUh?=
NB5	MnXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4rzfWlEPTB;OUW2MlYhdk1?	MmfMV2FPT0WU
NCI-H292	M3LieGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3U[JlKSzVyPUm3OE4{OiCwTR?=	M{nOT3NCVkeHUh?=
A101D	NGrXWlBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH\GNIFKSzVyPUm5NE4yQSCwTR?=	M2PlVHNCVkeHUh?=
NCI-H1648	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV:4OZRGUUN3ME25PVgvPTFibl2=	NVXRUodpW0GQR1XS
EKVX	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV35NpJnUUN3ME2xMlAyOjlizszN	M3PRSHNCVkeHUh?=
SW1710	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;BSoNQUUN3ME2xMlA1OjN\|IN88US=>	M2PkNHNCVkeHUh?=
WM-115	NV\tZXN{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MoXzTWM2OD1zLkC2OlU3KM7:TR?=	MlmwV2FPT0WU
CAL-54	NYLtRXJmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVL6eYZPUUN3ME2xMlA4ODhzIN88US=>	Mnr0V2FPT0WU
TGBC24TKB	M4PSPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTOTWM2OD1zLkC4NFQ2KM7:TR?=	NVzicWNSW0GQR1XS
NCI-H520	NXnwT\|JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HZTWlEPTB;MT6wPFk3PyEQvF2=	NHztbY1USU6JRWK=
D-423MG	NVX4[GRZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXLJR\|UxRTFwMEm5OlIh\|ryP	NXP4OnB1W0GQR1XS
BFTC-905	NXPUcopOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXftZXJPUUN3ME2xMlE{PDR7IN88US=>	MVvTRW5ITVJ?
HT	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWHNTmsxUUN3ME2xMlE{PDd6IN88US=>	NIjIdmpUSU6JRWK=
CTB-1	MoC5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4K4ZmlEPTB;MT6xOFI6OyEQvF2=	NGPnOpZUSU6JRWK=
Hs-578-T	MlzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYfhU5hJUUN3ME2xMlE6PTZ3IN88US=>	MlflV2FPT0WU
HuH-7	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVz5W\|U3UUN3ME2xMlIxQTR7IN88US=>	M{O2ZnNCVkeHUh?=
LB996-RCC	MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2XUXmlEPTB;MT6yNlE4PyEQvF2=	MXjTRW5ITVJ?
KYSE-270	NHfm[XNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmLTTWM2OD1zLkK5O\|M1KM7:TR?=	MVrTRW5ITVJ?
A4-Fuk	MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTFwMkm5PVMh\|ryP	MnntV2FPT0WU
A498	NFrwPYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTFwM{C0O\|Qh\|ryP	M2XMdnNCVkeHUh?=
SK-MEL-1	NXzWNZJpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVSyc3FSUUN3ME2xMlMxPjd7IN88US=>	NVe2OFljW0GQR1XS
AU565	M3XwT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33rcWlEPTB;MT6zNVg3OyEQvF2=	NEC0SG1USU6JRWK=
Saos-2	MoTRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGnzdFJKSzVyPUGuN\|MzODVizszN	Mnv5V2FPT0WU
A549	M2LDPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4rpVWlEPTB;MT6zPVk4KM7:TR?=	MYjTRW5ITVJ?
BFTC-909	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFrtPW1KSzVyPUGuOFM{ODVizszN	MX7TRW5ITVJ?
MDA-MB-415	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV\oOFhoUUN3ME2xMlQ5Pjl{IN88US=>	Mn35V2FPT0WU
639-V	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF7rOYpKSzVyPUGuOVAzPDVizszN	MUDTRW5ITVJ?
A704	MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mny5TWM2OD1zLkWwO\|g2KM7:TR?=	MnTuV2FPT0WU
PANC-03-27	M4ezOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHzBb4NKSzVyPUGuOVE1ODhizszN	M3rtdXNCVkeHUh?=
SK-MEL-28	NVzkcZFKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUXJR\|UxRTFwNU[wPFUh\|ryP	NEj6SWtUSU6JRWK=
Ramos-2G6-4C10	NFXhfmJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGXocWxKSzVyPUGuOlA4PDZizszN	NGr0NG5USU6JRWK=
HuP-T4	M1LmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NE\rRm1KSzVyPUGuOlA4PzhizszN	M{izSnNCVkeHUh?=
VA-ES-BJ	NXTwVFlrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTFwNkGyO{DPxE1?	NI\ocmxUSU6JRWK=
EFM-19	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF\2R\|ZKSzVyPUGuOlE5OSEQvF2=	MUXTRW5ITVJ?
G-401	MoW2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlrVTWM2OD1zLk[yNVY1KM7:TR?=	NYfZRWFTW0GQR1XS
D-566MG	NUPocId1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NFHjTFhKSzVyPUGuOlI2OyEQvF2=	MofGV2FPT0WU
JVM-3	MonKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NE\Wd3pKSzVyPUGuOlQ5PzVizszN	MXvTRW5ITVJ?
TK10	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2j4eWlEPTB;MT62O\|A5OyEQvF2=	MUPTRW5ITVJ?
BT-20	MkjYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYHtZlRxUUN3ME2xMlY5QTB{IN88US=>	NFqxUItUSU6JRWK=
EGI-1	NV;5RYhQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlzFTWM2OD1zLki0O\|AyKM7:TR?=	MYDTRW5ITVJ?
EW-16	Ml7GS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3nYdmlEPTB;MT64OVE5OiEQvF2=	M4ezbXNCVkeHUh?=
NCI-H2228	NWjpXmxsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWHCN4tTUUN3ME2xMlg2OjB\|IN88US=>	MlXoV2FPT0WU
BB49-HNC	MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGTwb\|JKSzVyPUGuPFg3QTJizszN	MVzTRW5ITVJ?
G-402	NFTJXYFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mn\ITWM2OD1zLki5O\|k4KM7:TR?=	MYrTRW5ITVJ?
NCI-H526	M2\3SWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4PaXWlEPTB;MT65NVM6KM7:TR?=	M4\IenNCVkeHUh?=
ME-180	NUGx[XJIT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{DTUWlEPTB;MT65N\|Q4PyEQvF2=	NX\HZZZsW0GQR1XS
PFSK-1	NISzdpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUnyV3MzUUN3ME2xMlk1PDV6IN88US=>	NHzNRoNUSU6JRWK=
TYK-nu	M4jSR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF7kT\|lKSzVyPUGuPVU5OjNizszN	MUPTRW5ITVJ?
HOS	M2WzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4\kVmlEPTB;MT65O\|k1QCEQvF2=	MXnTRW5ITVJ?
T98G	MoPmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYTJR\|UxRTFwOUmwNFYh\|ryP	NFTwSYZUSU6JRWK=
SK-MES-1	NWrCUI1DT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnPaTWM2OD1{LkCxN\|MzKM7:TR?=	M4nBTXNCVkeHUh?=
SNB75	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXjtZYdjUUN3ME2yMlAyPTRzIN88US=>	MYfTRW5ITVJ?
LAMA-84	NY[1[nUxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkG3TWM2OD1{LkCyOlg6KM7:TR?=	M3eyR3NCVkeHUh?=
CAL-39	MofxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYrJR\|UxRTJwMEOyPEDPxE1?	NYH3cGVLW0GQR1XS
LOXIMVI	Ml\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPEPYRKSzVyPUKuNFQxQDRizszN	M3TLNXNCVkeHUh?=
NH-12	NGHvbHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEDJOGhKSzVyPUKuNFU1OjRizszN	MkTaV2FPT0WU
NCI-H1048	M3\BeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWLDPWw2UUN3ME2yMlExPTJizszN	NHf2O4JUSU6JRWK=
KS-1	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NFy5OXJKSzVyPUKuNVExODFizszN	NX7nXHROW0GQR1XS
NCI-N87	NUXONZJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnTQTWM2OD1{LkGzN\|g1KM7:TR?=	MkXnV2FPT0WU
CHP-212	NWLOc4c5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3i2SWlEPTB;Mj6xPFQ1OiEQvF2=	NIj2XZhUSU6JRWK=
HCC1419	NEDwV2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlTHTWM2OD1{LkKxNVE2KM7:TR?=	NG\GXZpUSU6JRWK=
ES1	MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MY\JR\|UxRTJwMkGzNlYh\|ryP	MmLRV2FPT0WU
NCI-H2030	NV65clZqT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUHz[IV7UUN3ME2yMlI1OTJ\|IN88US=>	MWfTRW5ITVJ?
EW-22	NE\yNXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Mnu2TWM2OD1{LkK1NFY4KM7:TR?=	NFKyc2tUSU6JRWK=
A431	NU\WdmpMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2X5fGlEPTB;Mj6yO\|M2PCEQvF2=	NIjmcmpUSU6JRWK=
SF126	M1f6S2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M33De2lEPTB;Mj6zNFYzPSEQvF2=	NXXQS5lYW0GQR1XS
SF295	NULabXZrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mki3TWM2OD1{LkOxOVI1KM7:TR?=	MYLTRW5ITVJ?
D-502MG	NYnKOmk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NF3wb2JKSzVyPUKuN\|I1PjFizszN	M1HkPXNCVkeHUh?=
HCC2157	Mnz0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVfJR\|UxRTJwM{K5Nlch\|ryP	NXHneVFEW0GQR1XS
D-283MED	NHnWZY5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LP[WlEPTB;Mj6zOVkzPiEQvF2=	NHj4XWtUSU6JRWK=
SNU-423	MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVXJR\|UxRTJwNECxO\|Eh\|ryP	NGnsdWtUSU6JRWK=
SK-LU-1	NV\uPVlRT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXTJR\|UxRTJwNES1PFYh\|ryP	M3fCR3NCVkeHUh?=
22RV1	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGjIOmxKSzVyPUKuOFU3OTdizszN	M4KzdHNCVkeHUh?=
SW1088	NEHRdplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1LWR2lEPTB;Mj60PVIyOyEQvF2=	MnfNV2FPT0WU
HT-3	NXfQV25TT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEH6VW5KSzVyPUKuOFkzPTlizszN	MULTRW5ITVJ?
NCI-H1666	Mme1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MV3JR\|UxRTJwNUGxNFQh\|ryP	MWPTRW5ITVJ?
EM-2	NYLqZ2U4T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NETkdGVKSzVyPUKuOVEyPjlizszN	NFn2PGNUSU6JRWK=
SNU-449	NV\WeZpWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWjJR\|UxRTJwNUewNVQh\|ryP	NGPFepZUSU6JRWK=
786-0	NWPHSY44T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NILHdpRKSzVyPUKuOVkzOzhizszN	M4C1U3NCVkeHUh?=
SKG-IIIa	NIm2[JlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUnJR\|UxRTJwNkW5N\|kh\|ryP	MVrTRW5ITVJ?
MEL-HO	M1\jfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYPB[m44UUN3ME2yMlY4PjN2IN88US=>	M{DWOXNCVkeHUh?=
LCLC-97TM1	MmPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MmHZTWM2OD1{Lk[5NlY4KM7:TR?=	NWLBdJI3W0GQR1XS
MKN7	M2H4dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NF3U[\|FKSzVyPUKuO\|A4PTRizszN	MnHnV2FPT0WU
5637	M2jrT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTJwN{GwN\|Uh\|ryP	NXXXRmdvW0GQR1XS
HOP-92	NHTEWpdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2\xNGlEPTB;Mj63OFcyPyEQvF2=	MYfTRW5ITVJ?
MDA-MB-157	M1zzXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUnFdIgyUUN3ME2yMlgzODJ\|IN88US=>	MnTnV2FPT0WU
NB12	MnTMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkPaTWM2OD1{Lki0PVE1KM7:TR?=	M2HnWnNCVkeHUh?=
DMS-273	NGnNeFZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFTMOINKSzVyPUKuPFY1PyEQvF2=	NUG3[Wo4W0GQR1XS
HCC70	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NF;CNWFKSzVyPUKuPFY2QDlizszN	MWfTRW5ITVJ?
YKG-1	NFjlU4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFfzcldKSzVyPUOuNFM4QDdizszN	M1;wV3NCVkeHUh?=
NCI-H28	NUHOSItlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHPk[nRKSzVyPUOuNFUzQTFizszN	M2PXd3NCVkeHUh?=
HN	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NGDKUoZKSzVyPUOuNFY3OzZizszN	MmntV2FPT0WU
HT-1080	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3HETmlEPTB;Mz6wPFYxPiEQvF2=	MmH3V2FPT0WU
HPAF-II	NH[yfpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYTBSmJxUUN3ME2zMlExODZ6IN88US=>	M3nzRnNCVkeHUh?=
U-2-OS	NH\WPXhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXTVVHJvUUN3ME2zMlE{Pzh{IN88US=>	M1vXTXNCVkeHUh?=
SNU-387	MoLlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlXNTWM2OD1\|LkG2N\|Y1KM7:TR?=	MmfHV2FPT0WU
Becker	MkC2S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NFTwOnhKSzVyPUOuNVY5ODhizszN	MYDTRW5ITVJ?
BHY	M3\2RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGfOSo9KSzVyPUOuNlU2PzFizszN	MVvTRW5ITVJ?
HTC-C3	NVrQdoRFT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjzTWM2OD1\|LkK5N\|UzKM7:TR?=	M2TKd3NCVkeHUh?=
M14	MlXzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYTMXllsUUN3ME2zMlMxPjZ\|IN88US=>	MnTxV2FPT0WU
COR-L23	MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\HNIw5UUN3ME2zMlM4Ojd7IN88US=>	MXXTRW5ITVJ?
C32	NHTjTYdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXnEeGlYUUN3ME2zMlQyPTB6IN88US=>	NX;KW25tW0GQR1XS
Mewo	NFTFOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NID5OYpKSzVyPUOuOFIyQDJizszN	MUXTRW5ITVJ?
TE-8	M2rET2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3PXOmlEPTB;Mz60PFI2QSEQvF2=	NXrnemJrW0GQR1XS
RPMI-2650	Ml6wS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3\0[WlEPTB;Mz62NFY{PyEQvF2=	MVLTRW5ITVJ?
AGS	NUjvNVF2T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWTpeWIxUUN3ME2zMlYzPDZ2IN88US=>	NWj5V5poW0GQR1XS
MZ2-MEL	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoXwTWM2OD1\|Lk[2NVM5KM7:TR?=	M{TSdHNCVkeHUh?=
Calu-3	NX3YV3ljT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1G5SWlEPTB;Mz63NVI5PyEQvF2=	MXrTRW5ITVJ?
SJSA-1	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1rUemlEPTB;Mz63NVMyPSEQvF2=	M3LYfnNCVkeHUh?=
SW962	NUXmfIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWHJR\|UxRTNwN{K2N\|Yh\|ryP	NEjheI5USU6JRWK=
PC-14	Mm[3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2XmSmlEPTB;Mz63N\|IzOiEQvF2=	MnXIV2FPT0WU
SW1573	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MW\JR\|UxRTNwN{WzOFgh\|ryP	NGD1bZZUSU6JRWK=
769-P	NX\QS2JoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mk[0TWM2OD1\|LkiyO\|Q{KM7:TR?=	M1nkNXNCVkeHUh?=
KNS-62	MmjRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4\QWGlEPTB;Mz65NlM{QCEQvF2=	M1P2UXNCVkeHUh?=
NCI-H747	MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3G2WmlEPTB;ND6wOVY{QCEQvF2=	M1TpR3NCVkeHUh?=
LN-405	MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG\CWWpKSzVyPUSuNVU4OjhizszN	NXv1NHFlW0GQR1XS
OVCAR-8	M4HKcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUPFNYZYUUN3ME20MlIzPTR\|IN88US=>	M4LUXXNCVkeHUh?=
DMS-114	MmfuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWXJR\|UxRTRwMkO4PVEh\|ryP	NF3sTY1USU6JRWK=
NCI-H2126	NIHvbnFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{G1PGlEPTB;ND6yOFU2QCEQvF2=	NFz6ZXBUSU6JRWK=
TCCSUP	MVLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MkHQTWM2OD12LkK0O\|g5KM7:TR?=	MXrTRW5ITVJ?
SK-N-FI	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3Ht[GlEPTB;ND6yOVM{OiEQvF2=	MkjSV2FPT0WU
HCE-4	M17XTmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXKzRms1UUN3ME20MlI4OTl5IN88US=>	NIC4fVZUSU6JRWK=
DK-MG	NFr6fWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUfJR\|UxRTRwM{CzPUDPxE1?	Mk\HV2FPT0WU
RO82-W-1	MnXwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnvYTWM2OD12LkOyOVg1KM7:TR?=	NVjEVWZEW0GQR1XS
A2780	NXfFVVRDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTRwM{[2PFIh\|ryP	MXnTRW5ITVJ?
ETK-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MVPJR\|UxRTRwM{ewOVIh\|ryP	MkP1V2FPT0WU
FADU	NVryW5RZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVzZ[W5OUUN3ME20MlM4PDZ5IN88US=>	NIWyOW1USU6JRWK=
CAL-12T	NGTJNoFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFvzO2NKSzVyPUSuOFE1OTNizszN	MV;TRW5ITVJ?
647-V	NFm4[nJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHsbnJGUUN3ME20MlQ1ODJ{IN88US=>	MWLTRW5ITVJ?
TGBC1TKB	NFL3dGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXHpOHpNUUN3ME20MlQ2OTF\|IN88US=>	M3SyenNCVkeHUh?=
LU-99A	M1\hT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M2rxcmlEPTB;ND60OlA3KM7:TR?=	MoTFV2FPT0WU
CAL-33	NH\RTpBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvxd\|NKSzVyPUSuOVI1PTZizszN	M4jBN3NCVkeHUh?=
LU-134-A	NHSyb3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHITWM2OD12LkWyO\|Q2KM7:TR?=	NFnkTYVUSU6JRWK=
NCI-H1355	M{nGfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NGLuZ3RKSzVyPUSuOVUyPDZizszN	NWXhRlhrW0GQR1XS
RPMI-7951	NXfOXo54T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHYTWM2OD12LkW3NFAzKM7:TR?=	NUfEUlZxW0GQR1XS
TE-1	M13YfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFS3XXpKSzVyPUSuOlYyPDNizszN	NV24cWFLW0GQR1XS
OE33	NEGyTGNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1rONmlEPTB;ND63NFUyOSEQvF2=	NX;UOmN3W0GQR1XS
CAL-51	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUXJR\|UxRTRwN{GwPFIh\|ryP	NXjJcnl7W0GQR1XS
SW1783	NH3KTmdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2nrXWlEPTB;ND63OVMxQCEQvF2=	M2CzOnNCVkeHUh?=
BT-474	MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M1;HNmlEPTB;ND63OlM5PCEQvF2=	MWTTRW5ITVJ?
KYSE-520	NGHLOWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M13UfGlEPTB;ND64O\|M6OiEQvF2=	NEThbVhUSU6JRWK=
8-MG-BA	NETFbVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWDJR\|UxRTRwOEi1OVch\|ryP	MnrUV2FPT0WU
IA-LM	M3HaZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NHTTe\|RKSzVyPUSuPVk1OzVizszN	NEjiPZVUSU6JRWK=
SW954	NYfWNIFPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYHJR\|UxRTRwOUm0OFMh\|ryP	MmPuV2FPT0WU
RPMI-8226	NXjBb4dOT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYHZfHl1UUN3ME21MlA2PDZzIN88US=>	M4i0enNCVkeHUh?=
MKN1	NFjBe2xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmXhTWM2OD13LkC3PVI4KM7:TR?=	NYLieZhUW0GQR1XS
A375	NWTYcG1{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEG5WWNKSzVyPUWuNFkzPTZizszN	MlToV2FPT0WU
8305C	M3v1[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnXUTWM2OD13LkC5PFg4KM7:TR?=	MofQV2FPT0WU
CAL-62	NFLRcFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M2LyOGlEPTB;NT6xPFI2QSEQvF2=	Mk\JV2FPT0WU
NB10	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX\JR\|UxRTVwMkK3OFQh\|ryP	NWjzXFVXW0GQR1XS
OC-314	NXeyNFNDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV7FRW44UUN3ME21MlM4PDR2IN88US=>	NEfrWZlUSU6JRWK=
PSN1	NFTpTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUHJR\|UxRTVwM{iyPFYh\|ryP	NV\mVJZTW0GQR1XS
GR-ST	NYjWNpZxT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmj4TWM2OD13LkO4N\|IzKM7:TR?=	MkPGV2FPT0WU
P12-ICHIKAWA	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MX;JR\|UxRTVwNECxJO69VQ>?	MkPnV2FPT0WU
NCI-H1092	M3TveGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MX;JR\|UxRTVwNEGxOFgh\|ryP	NUXzNVVjW0GQR1XS
SCC-4	MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3\qPGlEPTB;NT60NVM2PSEQvF2=	M2nuV3NCVkeHUh?=
TE-6	NYnl[nNpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVzJR\|UxRTVwNEG4NVYh\|ryP	MUTTRW5ITVJ?
DOHH-2	MoKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2Dab2lEPTB;NT60NlI1QCEQvF2=	M3fJOHNCVkeHUh?=
SW684	NH3U[YdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWnJR\|UxRTVwNk[zPFUh\|ryP	MYnTRW5ITVJ?
CP50-MEL-B	NX;2[ZpmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnXvTWM2OD13Lk[4Olg1KM7:TR?=	M{HQd3NCVkeHUh?=
UM-UC-3	M2G1TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MljFTWM2OD13LkeyNlMyKM7:TR?=	MYjTRW5ITVJ?
LC-2-ad	NX3jRoRYT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3f0ZWlEPTB;NT63PFI2OSEQvF2=	Mn7DV2FPT0WU
PC-3	M4\5PWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFvmNotKSzVyPUWuPVE3OTVizszN	NUXkPVhGW0GQR1XS
CAN	MlXRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MoXrTWM2OD13LkmyPFIh\|ryP	MoXzV2FPT0WU
ESS-1	NETZ[\|dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkHyTWM2OD13Lkm3PFY6KM7:TR?=	MlTJV2FPT0WU
ATN-1	NWTjblJHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGXHOnJKSzVyPU[uNFU2PjhizszN	NIPJNG5USU6JRWK=
BxPC-3	NFL3cWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWHpXplbUUN3ME22MlA5OjF7IN88US=>	M3jISHNCVkeHUh?=
KYSE-150	NVnrUpppT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXTsVpZyUUN3ME22MlEzPDd4IN88US=>	M2fjdnNCVkeHUh?=
RPMI-8866	M4nMO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnzmTWM2OD14LkG5NVY{KM7:TR?=	NXXIPW54W0GQR1XS
SW780	NEHUZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NVf4OXB2UUN3ME22MlIxPDJizszN	MXrTRW5ITVJ?
A388	NI\jfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3\yNGlEPTB;Nj6yN\|EyPSEQvF2=	NXPXXJY{W0GQR1XS
NCI-H1437	NH3hOWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWfJR\|UxRTZwMkSwO\|Mh\|ryP	NEDkUY9USU6JRWK=
NCI-H1755	NUDT[XJGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUPJR\|UxRTZwM{[2NVIh\|ryP	MXjTRW5ITVJ?
LS-123	M1nrZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NWfSSWtTUUN3ME22MlQxPTJzIN88US=>	M4HxTXNCVkeHUh?=
CaR-1	NEPSZ5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MUTJR\|UxRTZwNE[zO\|Mh\|ryP	MXfTRW5ITVJ?
RT-112	NWTjToxTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXvUS2NrUUN3ME22MlYxOzN6IN88US=>	MlrQV2FPT0WU
CGT	NWjjfFh6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NV;sU4lqUUN3ME22Mlc{PjhzIN88US=>	NF7aSHVUSU6JRWK=
SW626	M2XK[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MmnHTWM2OD14LkezPVQ3KM7:TR?=	MVzTRW5ITVJ?
AsPC-1	NGjYU5VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MknvTWM2OD14Lke0OVA4KM7:TR?=	MX7TRW5ITVJ?
SBC-5	MljKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTZwOUeyPVch\|ryP	MoPUV2FPT0WU
SF539	MoXGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HoXWlEPTB;Nj65PVM{OyEQvF2=	M4LxWXNCVkeHUh?=
TI-73	MnzzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MX3JR\|UxRTdwME[yPFUh\|ryP	M{HYPXNCVkeHUh?=
MHH-ES-1	NF7sXYpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MWHJR\|UxRTdwMEe3OlIh\|ryP	MXrTRW5ITVJ?
KYSE-510	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mnf2TWM2OD15LkC4OFMzKM7:TR?=	NI\mOIZUSU6JRWK=
EW-1	M1PhWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1i1OGlEPTB;Nz6zOlk6PiEQvF2=	MUfTRW5ITVJ?
SK-OV-3	MnHQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXHDcJJvUUN3ME23MlM6PDN{IN88US=>	NWfVVpdjW0GQR1XS
MC-IXC	NIrnXmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NH7yOZJKSzVyPUeuOFE6PzJizszN	MWLTRW5ITVJ?
HSC-2	NWXzWGpZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHi0XXVKSzVyPUeuOFI4ODVizszN	NWfyPG81W0GQR1XS
NCI-H2342	MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLDTWM2OD15LkWxOFkh\|ryP	MVzTRW5ITVJ?
NCI-H1792	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWXJR\|UxRTdwNUG3NVEh\|ryP	MYjTRW5ITVJ?
HT-1376	NHroPXlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1TnTmlEPTB;Nz64O\|c4QCEQvF2=	Ml\SV2FPT0WU
EW-13	NIKweYVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MW\JR\|UxRTdwOEm5O\|ch\|ryP	MVvTRW5ITVJ?
no-11	MoX3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnHOTWM2OD15LkmwNVc1KM7:TR?=	MWrTRW5ITVJ?
Daoy	MVnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXrxd5RGUUN3ME23Mlk1OzJzIN88US=>	NWTnbm41W0GQR1XS
COLO-800	NX76VlhoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MYjJR\|UxRThwMESxOlIh\|ryP	MW\TRW5ITVJ?
GB-1	MojmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NGPCWm5KSzVyPUiuNFY2PjVizszN	M3X5W3NCVkeHUh?=
SJRH30	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnTITWM2OD16LkG1PFc5KM7:TR?=	Ml7xV2FPT0WU
NCI-H2291	M1PMfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1Hk[mlEPTB;OD6yPVE5PyEQvF2=	NXLncoJLW0GQR1XS
J82	NULVcnZXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVu0THdKUUN3ME24MlI6PDlzIN88US=>	MX3TRW5ITVJ?
NCI-H596	NHeyU5RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NELGZWFKSzVyPUiuN\|E1PTNizszN	NGL3c2pUSU6JRWK=
RERF-LC-MS	M{GwZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3TlcGlEPTB;OD6zOFg2PiEQvF2=	M4WyWnNCVkeHUh?=
RH-18	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIjXOHVKSzVyPUiuN\|UxPDZizszN	MYLTRW5ITVJ?
SW48	M{X0bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnLmTWM2OD16LkW5OFU{KM7:TR?=	MlnkV2FPT0WU
RD	NVq2UVNJT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NUXw[IhwUUN3ME24MlU6OzlzIN88US=>	NYTsWZQ4W0GQR1XS
MS-1	NWDDXpNWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1;mS2lEPTB;OD62NVM5PyEQvF2=	NEK4cXNUSU6JRWK=
ES6	M3nQOGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NH7wZZhKSzVyPUiuO\|MyOTlizszN	MYHTRW5ITVJ?
TE-12	NEWySYRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYnJR\|UxRThwN{e1NFUh\|ryP	MXTTRW5ITVJ?
DBTRG-05MG	NUC2eGRGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MV;JR\|UxRThwOUGyNVch\|ryP	NFftXlZUSU6JRWK=
KINGS-1	MnKxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NEfoWXRKSzVyPUiuPVI6OzhizszN	MlrwV2FPT0WU
HLE	NVTtVW97T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M4HjcmlEPTB;OD65N\|c5PSEQvF2=	M1TWO3NCVkeHUh?=
MHH-NB-11	NUHxVmlHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEjQZZdKSzVyPUmuNFE5OzlizszN	M4flVnNCVkeHUh?=
U-87-MG	MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYrJR\|UxRTlwMkSzNlEh\|ryP	MWnTRW5ITVJ?
MN-60	MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NWDIOHlWUUN3ME25MlI1PTR{IN88US=>	M1zwVHNCVkeHUh?=
SAS	MoK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NY\lS29SUUN3ME25MlI2PThzIN88US=>	MWnTRW5ITVJ?
NCI-H446	M33RSGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEnXcY1KSzVyPUmuN\|YyKM7:TR?=	NIrMWGlUSU6JRWK=
C-33-A	NIW5SpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYnSc2oxUUN3ME25MlQ{QTh6IN88US=>	NVrUTHdxW0GQR1XS
RXF393	M4[1bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFH6RVNKSzVyPUmuOFcxODJizszN	M{\WZnNCVkeHUh?=
CGTH-W-1	NXjqbndMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTlwNEmzPFQh\|ryP	NXzuZ2ZQW0GQR1XS
RCM-1	MmOzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnTFTWM2OD17Lk[zPFAyKM7:TR?=	NX\OeI02W0GQR1XS
SN12C	NG\XfmFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3PofGlEPTB;OT62OVM{QCEQvF2=	NHjsNVhUSU6JRWK=
KLE	NVzuPXk3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUHJR\|UxRTlwN{CwNFkh\|ryP	M3uxXHNCVkeHUh?=
EFO-21	M13EXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3\iOmlEPTB;OT63O\|M5OiEQvF2=	MkTmV2FPT0WU
KYSE-70	MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MUPJR\|UxRTlwOEiwNVEh\|ryP	NVG2[VRyW0GQR1XS
D-247MG	M2nQWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3WwcWlEPTB;MUCuNFU3QCEQvF2=	MorXV2FPT0WU
MPP-89	MoHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnzmTWM2OD1zMD6wPVQ3KM7:TR?=	MmXvV2FPT0WU
RVH-421	NEfNW5lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NUfTZVFXUUN3ME2xNE4yPTB3IN88US=>	NEP3bW1USU6JRWK=
NCI-H460	NVHuZ3pZT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml:0TWM2OD1zMD6yPFA3KM7:TR?=	NHzM[ZFUSU6JRWK=
NOMO-1	NVnGO2tQT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXT4fIJ4UUN3ME2xNE4{PTN{IN88US=>	M1ToSnNCVkeHUh?=
DEL	NVXVRYhrT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGn0RXNKSzVyPUGwMlM4QTRizszN	NV7qVG5RW0GQR1XS
HT55	M3yxWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M{LTWGlEPTB;MUCuOlIxPSEQvF2=	Mn[xV2FPT0WU
MC116	NXToTIhzT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHvCemVKSzVyPUGwMlY3PTVizszN	MXPTRW5ITVJ?
BB30-HNC	NYm5TpBpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M3S2bWlEPTB;MUCuOlY6KM7:TR?=	MkDqV2FPT0WU
DJM-1	NI\oU2JIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M3HMfGlEPTB;MUCuOlk1QSEQvF2=	NWqz[HFvW0GQR1XS
ZR-75-30	Mo\4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2f1WmlEPTB;MUCuPVQ1OSEQvF2=	MYDTRW5ITVJ?
U-118-MG	M4DaXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3jPZ2lEPTB;MUCuPVg6PiEQvF2=	M4Pod3NCVkeHUh?=
MSTO-211H	NF7qUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MmTBTWM2OD1zMT6wO\|E3KM7:TR?=	MXPTRW5ITVJ?
SW837	MmXXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				Mnu5TWM2OD1zMT6wPVQ6KM7:TR?=	NUD5V\|BNW0GQR1XS
HuCCT1	M1LUN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXy4eGR4UUN3ME2xNU4yOjhzIN88US=>	M{\0U3NCVkeHUh?=
RCC10RGB	M3XmUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1\KdmlEPTB;MUGuNVM2KM7:TR?=	Mli0V2FPT0WU
NMC-G1	MoTrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVfafIlWUUN3ME2xNU4yPDl\|IN88US=>	MY\TRW5ITVJ?
NCI-H650	M1v0eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWnJR\|UxRTFzLkO3PVQh\|ryP	Ml\wV2FPT0WU
HEC-1	M4CwWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MU\JR\|UxRTFzLkSzNlgh\|ryP	Mk\nV2FPT0WU
DU-4475	NH3xb3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHvkc5lKSzVyPUGxMlc{QTNizszN	NGnQSI1USU6JRWK=
DSH1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoqyTWM2OD1zMT63OlA3KM7:TR?=	M1XtZXNCVkeHUh?=
HCC1569	NVixXnBbT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MUnJR\|UxRTFzLke2O\|gh\|ryP	Mlf1V2FPT0WU
HCC1187	M{HTVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn3LTWM2OD1zMT64OVg5KM7:TR?=	Moe1V2FPT0WU
EW-11	MofuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MYnJR\|UxRTFzLkm0O\|Qh\|ryP	NX3B[5YzW0GQR1XS
LB2518-MEL	NYDNfmNkT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NXjVR4xRUUN3ME2xNk4xPTlizszN	NWLkXXZDW0GQR1XS
KALS-1	NHnFZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NFjGZ2lKSzVyPUGyMlg2PTNizszN	M1HkN3NCVkeHUh?=
8505C	NYficYJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NHHqeGlKSzVyPUGyMlg5PSEQvF2=	NVLUR2RCW0GQR1XS
SK-N-DZ	NVTPTHczT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mmr4TWM2OD1zMz6wOFU{KM7:TR?=	MWnTRW5ITVJ?
CHP-134	NWjXN2VMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NVTMcnlQUUN3ME2xN{4yOTV6IN88US=>	NWO1NlFWW0GQR1XS
HCE-T	MkPsS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWPTPHR3UUN3ME2xN{4zOzZ2IN88US=>	Mk[3V2FPT0WU
LB-831-BLC	M4O1Umdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NEDDZmxKSzVyPUGzMlYzPDZizszN	MUTTRW5ITVJ?
OVCAR-4	M{\PUWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7qTWM2OD1zMz62OVI1KM7:TR?=	NUPESmd{W0GQR1XS
SW756	NV;oc4hNT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVrJR\|UxRTF\|LkeyOFYh\|ryP	MWnTRW5ITVJ?
OCUB-M	NH;aTG9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NI\JOWpKSzVyPUGzMlgyPTZizszN	NXK2bGdzW0GQR1XS
SW982	NXPCUVlmT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHBTWM2OD1zMz64Nlc3KM7:TR?=	M4nLT3NCVkeHUh?=
DB	NHTzRWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXG4Wo41UUN3ME2xN{45Ozh2IN88US=>	MYTTRW5ITVJ?
H-EMC-SS	M4DtOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTF\|LkmxN\|kh\|ryP	MkLwV2FPT0WU
VMRC-RCZ	M1jldWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1nqT2lEPTB;MUSuNFAyPSEQvF2=	MUPTRW5ITVJ?
CAKI-1	MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M13UemlEPTB;MUSuNFE{OiEQvF2=	NGrNdIJUSU6JRWK=
GI-1	NX7kUYRpT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{nzRmlEPTB;MUSuNFY2QCEQvF2=	MnvnV2FPT0WU
Ca9-22	NH3JfXVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{HweGlEPTB;MUSuOlA2PCEQvF2=	MnHjV2FPT0WU
TE-5	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NG[0TFJKSzVyPUG0MlczODhizszN	NUfnXW05W0GQR1XS
EFO-27	MkDjS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MULJR\|UxRTF2Lke2NlIh\|ryP	MX;TRW5ITVJ?
CAL-72	NEX3XnRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NEPM[5lKSzVyPUG0Mlc4QDNizszN	MXXTRW5ITVJ?
GP5d	NY\kW4t[T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH36N4dKSzVyPUG1MlA1PzRizszN	M3rH[XNCVkeHUh?=
CAS-1	NH\QeolIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NWjqSY95UUN3ME2xOU4xPjZizszN	NIHET5dUSU6JRWK=
A2058	M3XqVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MYnJR\|UxRTF3LkW2N\|gh\|ryP	NX\j[\|JJW0GQR1XS
PANC-08-13	NW[3W\|ZST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NITzV4hKSzVyPUG1MlY5PTlizszN	NXnTNYFmW0GQR1XS
Detroit562	MoP3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MorFTWM2OD1zNT65NVM6KM7:TR?=	Mk\JV2FPT0WU
PANC-10-05	NWnrVlQ{T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MXjJR\|UxRTF4LkC4NlEh\|ryP	NF7iXY1USU6JRWK=
KOSC-2	NELaTHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NYK1fWREUUN3ME2xOk4yOTJ3IN88US=>	M3XaPXNCVkeHUh?=
GT3TKB	NX\NXGFnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M2PrV2lEPTB;MU[uNVk5OSEQvF2=	NIHFSHJUSU6JRWK=
KM-H2	MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVvQSGpxUUN3ME2xOk4{PjR4IN88US=>	NEjrR5lUSU6JRWK=
LB771-HNC	MmO3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUHO[WYxUUN3ME2xOk41PDJ{IN88US=>	MWjTRW5ITVJ?
SF268	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3yN4lVUUN3ME2xOk41PTJizszN	NWLvPFJyW0GQR1XS
OE19	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2nuSGlEPTB;MU[uOVI1KM7:TR?=	NEfK[5pUSU6JRWK=
MLMA	Mmf3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1fQOGlEPTB;MU[uOVU4OSEQvF2=	MVLTRW5ITVJ?
MDA-MB-231	MkK4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2H4cWlEPTB;MU[uO\|E{PiEQvF2=	MUPTRW5ITVJ?
TGW	M4riOmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3y4VWlEPTB;MU[uPFExOiEQvF2=	NH72NYlUSU6JRWK=
MDA-MB-453	M1e3fWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M17y[mlEPTB;MUeuNFAxOyEQvF2=	NX;RWnpJW0GQR1XS
SNU-C2B	NIHZVnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NF75SoRKSzVyPUG3MlAzOzdizszN	Ml;VV2FPT0WU
A427	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NV;sUGNrUUN3ME2xO{4zOzN2IN88US=>	NGPpbmZUSU6JRWK=
SK-MEL-2	NIqybGVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NIXSbJRKSzVyPUG3MlMzOTNizszN	NWTFOY9CW0GQR1XS
KURAMOCHI	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1f6PGlEPTB;MUeuN\|g6PyEQvF2=	NXSwU4JDW0GQR1XS
IST-MEL1	NGfLdG5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1z4SmlEPTB;MUeuPVE5OiEQvF2=	NGG4[3RUSU6JRWK=
NCI-H1793	Mmf4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NWH2W3JXUUN3ME2xPE4yPThzIN88US=>	MU\TRW5ITVJ?
HCC1395	M4P0Smdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWDJR\|UxRTF6LkW2NVEh\|ryP	NEX3N2tUSU6JRWK=
NUGC-3	M33obmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXzxUZN3UUN3ME2xPE43PTh2IN88US=>	M3PyNHNCVkeHUh?=
BB65-RCC	MXvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MoHtTWM2OD1zOD62Olkh\|ryP	NY[4R3RUW0GQR1XS
RMG-I	NX;6eWVnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MlfWTWM2OD1zOD63N\|gzKM7:TR?=	M2fzbnNCVkeHUh?=
LS-513	M4HRcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYD2dIdYUUN3ME2xPE46OjJ6IN88US=>	NX7abFVSW0GQR1XS
MFM-223	NV3JRZVoT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWrJR\|UxRTF7LkC3NVYh\|ryP	MnTCV2FPT0WU
NCI-H727	M4LvPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoDnTWM2OD1zOT6zNlk2KM7:TR?=	MkDCV2FPT0WU
KP-4	MlHRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MkHETWM2OD1zOT64OVMyKM7:TR?=	NUnoSYx[W0GQR1XS
NB13	M3v4RWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWXJR\|UxRTF7Lki4N\|kh\|ryP	NGT3SGlUSU6JRWK=
UACC-893	MmLtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NYSzUGJ1UUN3ME2xPU46PzV5IN88US=>	NGHQTZpUSU6JRWK=
HT-1197	MmToS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M{HkZWlEPTB;MkCuNlk2QCEQvF2=	MkezV2FPT0WU
NCI-H2029	MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NU\CfGM{UUN3ME2yNE4{OjZ4IN88US=>	MWLTRW5ITVJ?
GI-ME-N	NYj2VHlPT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MVTJR\|UxRTJyLkOzO\|Mh\|ryP	NFH4T3BUSU6JRWK=
OVCAR-3	NYHT[GJ3T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkTpTWM2OD1{MD61PFIzKM7:TR?=	NYTRWZFSW0GQR1XS
HD-MY-Z	NYGzUY14T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NWDnXoY2UUN3ME2yNU4{Pjl4IN88US=>	NYLVPJU5W0GQR1XS
NTERA-S-cl-D1	MkLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1nzT2lEPTB;MkGuOlczOiEQvF2=	NXG2b25PW0GQR1XS
SCH	NIfqWWdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MlyxTWM2OD1{Mj60PVYh\|ryP	MUHTRW5ITVJ?
KARPAS-299	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4r5[mlEPTB;MkOuN\|g5PyEQvF2=	NIG2XHRUSU6JRWK=
NCI-H1650	MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mki1TWM2OD1{Mz65NlQyKM7:TR?=	NHXmRVVUSU6JRWK=
ACHN	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NVG2SIRzUUN3ME2yOE41PjV4IN88US=>	M{L6bXNCVkeHUh?=
M059J	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MWTJR\|UxRTJ2LkW2N\|Qh\|ryP	MnP3V2FPT0WU
AM-38	NWLpR2FsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NEO3dXRKSzVyPUK1MlQ5OSEQvF2=	NEfzWnBUSU6JRWK=
KG-1	M{C0XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NFXaVndKSzVyPUK1MlU1QTRizszN	MmC1V2FPT0WU
COLO-824	NUjzeZNjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkHqTWM2OD1{NT61OVk6KM7:TR?=	MYjTRW5ITVJ?
NCI-H1155	NIr4[XRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MYHJR\|UxRTJ3LkW4OFch\|ryP	NUjvOXdSW0GQR1XS
NCI-H441	M3TFWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MnrHTWM2OD1{NT63OFY2KM7:TR?=	MmrxV2FPT0WU
J-RT3-T3-5	NH\EbFBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NXKySWx6UUN3ME2yOk4{ODJ5IN88US=>	NU\hOHlCW0GQR1XS
JEG-3	MoPyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NUjj[ZNOUUN3ME2yOk43QDB3IN88US=>	MXnTRW5ITVJ?
RKO	Mn\ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ4Lke2N\|Ih\|ryP	MmLFV2FPT0WU
CAL-85-1	MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M2e1OGlEPTB;MkeuNlEyQCEQvF2=	MlnIV2FPT0WU
CAL-120	MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NXXIOphLUUN3ME2yO{43QTF2IN88US=>	Mnm5V2FPT0WU
NCI-H2452	MlTmS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2jaNWlEPTB;MkeuO\|cyPiEQvF2=	MYHTRW5ITVJ?
NCI-H1395	M1PZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkHpTWM2OD1{Nz63PFM{KM7:TR?=	MmnhV2FPT0WU
KYSE-450	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MnrFTWM2OD1{Nz65PFYzKM7:TR?=	NEHOV4ZUSU6JRWK=
S-117	Mk\zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2LkTGlEPTB;MkmuN\|g2PyEQvF2=	MX7TRW5ITVJ?
SW13	NHjYeWVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MkjKTWM2OD1{OT64OVE6KM7:TR?=	M4[2fnNCVkeHUh?=
ES3	Mm\yS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MljmTWM2OD1\|MD6zO\|M{KM7:TR?=	MWrTRW5ITVJ?
HCT-116	M3fSZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn\zTWM2OD1\|MD61OVU1KM7:TR?=	NFn3OY1USU6JRWK=
NCI-H1693	Mn;ZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXTJR\|UxRTNyLkW5OFIh\|ryP	NXvndW8{W0GQR1XS
VM-CUB-1	M{Dn[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M4HL[mlEPTB;M{CuOlQyOyEQvF2=	Mm\tV2FPT0WU
NCI-H2170	NFPnVHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NGOyfZNKSzVyPUOxMlU4QDRizszN	NYPCb4JqW0GQR1XS
ALL-PO	MnXrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1jpU2lEPTB;M{GuPFQzQCEQvF2=	M2Xo[3NCVkeHUh?=
NCI-H661	MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NX3pUJdjUUN3ME2zNk4xPjJ\|IN88US=>	MWfTRW5ITVJ?
NCI-H2347	MoTqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TvS2lEPTB;M{KuOFg{PyEQvF2=	MnXEV2FPT0WU
FTC-133	NIjiTlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{XkdWlEPTB;M{KuO\|A3KM7:TR?=	NIDoSYRUSU6JRWK=
COLO-829	MoHpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1m0T2lEPTB;M{OuN\|Q3PyEQvF2=	NGT0V5RUSU6JRWK=
GOTO	NYf2UlhnT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MX3JR\|UxRTN\|LkWyOVgh\|ryP	MnSwV2FPT0WU
YAPC	M1TWV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVLm[Xg3UUN3ME2zN{45OTV7IN88US=>	MkjJV2FPT0WU
LCLC-103H	NXjYfW9MT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M1fnOGlEPTB;M{SuNVYzPCEQvF2=	MX;TRW5ITVJ?
SiHa	NWH3T\|hUT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NH76[WdKSzVyPUO0MlM5OTdizszN	NHi1OIxUSU6JRWK=
LK-2	NXrwc5dlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGDIcZhKSzVyPUO0MlU4ODhizszN	M{fiZXNCVkeHUh?=
KP-N-YS	M2PKN2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MV\JR\|UxRTN2LkeyNFIh\|ryP	NWj2bmNjW0GQR1XS
NCI-SNU-1	NWTxWYlKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Mn\OTWM2OD1\|NT6xO\|kh\|ryP	M4nQZnNCVkeHUh?=
KNS-81-FD	NFTGSHRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NW\oTXpkUUN3ME2zOU43PjNizszN	NUKzR5dJW0GQR1XS
SCC-9	M{LsSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NUSyN\|ZMUUN3ME2zOk44OTR4IN88US=>	MWfTRW5ITVJ?
SH-4	M3HVUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M1vWUmlEPTB;M{[uO\|Mh\|ryP	MojwV2FPT0WU
HCC-1954	M{X2V2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NYLVPHdRUUN3ME2zO{4zPzJ7IN88US=>	MX;TRW5ITVJ?
BALL-1	MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NHH5PZhKSzVyPUO3MlU{OTZizszN	NEG1VXNUSU6JRWK=
BE-13	M4LDcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn7oTWM2OD1\|Nz63NFE5KM7:TR?=	NGnWb3hUSU6JRWK=
COLO-678	MkH5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4TpZmlEPTB;M{euPVQ{PyEQvF2=	MlTXV2FPT0WU
SK-MEL-3	M1q5TWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NY\xTGl5UUN3ME2zPE4zOzl5IN88US=>	M4ixXXNCVkeHUh?=
OAW-28	M1;ZWGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MVHJR\|UxRTN6Lk[zPUDPxE1?	MUjTRW5ITVJ?
CAMA-1	MnvSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NXKyR5RTUUN3ME2zPE46PjlzIN88US=>	MUTTRW5ITVJ?
C2BBe1	M{nFSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MoTwTWM2OD1\|OT64NVgh\|ryP	NHW4cppUSU6JRWK=
A3-KAW	MojCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVzadm1xUUN3ME20NE4{PjZzIN88US=>	Ml7rV2FPT0WU
SK-MEL-24	NG\RSJBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXzJR\|UxRTRyLkW5N\|Eh\|ryP	NFXVOZRUSU6JRWK=
KYSE-140	M3\Dcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NVXpSJN5UUN3ME20NE44OTZ3IN88US=>	MoHMV2FPT0WU
MOLT-16	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Ml;hTWM2OD12MT6xOVM3KM7:TR?=	NHzERWhUSU6JRWK=
CFPAC-1	M1nNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NU\3bZR7UUN3ME20Nk42OjFzIN88US=>	NWHaT4FMW0GQR1XS
NB14	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				Mm\4TWM2OD12Mj63NFI4KM7:TR?=	M2PiZnNCVkeHUh?=
COLO-792	M2rBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MXPJR\|UxRTR{Lki5OlEh\|ryP	NVTiZWY6W0GQR1XS
RH-1	MnLIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NX7WZnA6UUN3ME20N{41QDN4IN88US=>	MYDTRW5ITVJ?
NCI-H522	NVOxenA5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MkjyTWM2OD12ND6zOVY5KM7:TR?=	M1zXS3NCVkeHUh?=
Ca-Ski	MkPvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2fJOmlEPTB;NESuPFEyPCEQvF2=	NEj3d5hUSU6JRWK=
KGN	NV7XbJlCT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NYmxR49sUUN3ME20PE4{ODZ\|IN88US=>	M1\1WHNCVkeHUh?=
UACC-62	NYS1OnRTT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NGm4VlZKSzVyPUS4MlQxPzJizszN	MoLBV2FPT0WU
NCI-H358	MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				NIj0TpdKSzVyPUS5MlMxOThizszN	MlzkV2FPT0WU
LS-411N	NUXJUZduT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				NU\yfpp5UUN3ME20PU4{OTF6IN88US=>	NGPFXoVUSU6JRWK=
IST-MES1	MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmLSTWM2OD12OT61OlI2KM7:TR?=	NHjGXnJUSU6JRWK=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	p-AKT / AKT / p-FoxO3a / FoxO3a / PUMA; PubMed: 29137323 Oncotarget HCT116 cells were treated with 4μmol/L NVP-BKM120 or 4μmol/L Pictilisib for 24 hours. Indicated protein levels were analyzed by Western blotting. p-S6RP / S6RP; PubMed: 30042442 Cell Death Dis Western blot analysis of proteins as indicated in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. Vinculin was used as a loading control. p-4EBP1 / 4EBP1; PubMed: 25857298 Oncotarget Cells were treated with 0.5 μM GDC-0941 for the indicated time course and then collected for Western blot analysis of p-4EBP1. p-LRP6 / LRP6; PubMed: 25857298 Oncotarget MDAMB-231, HCC1937 and MCF7 cells were treated with 0.5 µM GDC-0941 for 1 hr, and cell lysates were used for immunoblot analyses. p-PAK / PAK1 / p-CRAF / RAF / p-MEK / MEK / p-ERK / ERK; PubMed: 24327733 Proc Natl Acad Sci U S A Cells were treated with 1 μM GDC-0941 for the indicated times, and lysates were probed with the indicated antibodies. Independent experiments were performed at least three times, and a representative result is shown.	29137323 30042442 25857298 24327733
Immunofluorescence	p65; PubMed: 30042442 Cell Death Dis Representative images of immunofluorescent staining of p65 cellular localization in 4T1 cells treated with 1 µM GDC-0941 or vehicle for 24 h. 4T1 cells were cultured alone or co-cultured with RAW264.7 macrophages. Representative images of three independent experiments are shown. beta-catenin; PubMed: 25857298 Oncotarget Cells were seeded on coverslips the day before the experiment and treated with 0.5 µM GDC-0941 for 18 hr. The immunofluorescence (IF) of beta-catenin is indicated as red fluorescence, and double staining with DAPI is blue. Magnification: 400 X for the left three panels. The right panel shows enlarged images from the white squares.	30042442 25857298
Growth inhibition assay	Cell viability; PubMed: 27117832 J Thorac Oncol The viability of the indicated cells treated with increasing concentrations of GDC-0941 (ranging from 70nM to 20 μM) for 72 hours, determined by CellTiter Glo Viability assay. The IC50 concentrations were calculated using GraphPad Prism program. The assay was performed in triplicate, and the error bars represent standard deviations.	27117832

In vivo

GDC-0941 shows limited microsomal metabolism, resulting in 78% oral bioavailability ^[5]. Administration of GDC-0941 at 75 mg/kg/day displays significant inhibitory effect against established human U87MG glioblastoma xenografts in female NCr athymic mice, with tumor growth inhibition of 83%. ^[1] Oral administration of GDC-0941 at 150 mg/kg/day inhibits the growth of HER2-amplified, trastuzumab-resistant MDA-MB-361.1 xenografts in mice, and significantly delays the tumor progression, in association with potent induced apoptosis in tumors. ^[2] GDC-0941 (75 mg/kg/day) treatment for 2 weeks induces ~40% reduction in tumor volume of spontaneous B-cell follicular lymphomas developed in PTEN+/-LKB1+/hypo mice, accompanied by ablation of phosphorylation of Akt, S6K and SGK (serum and glucocorticoid protein kinase) protein kinases. ^[4]

Protocol

Kinase Assay: ^[1]	+ Expand Scintillation proximity assay: Recombinant human PI3Kα, PI3Kβ, and PI3Kδ are coexpressed in a Sf9 baculovirus system with the p85α regulatory subunit and purified as GST-fusion proteins using affinity chromatography on glutathione-sepharose. Recombinant human PI3Kγ is expressed as monomeric GST-fusions and purified similarly. GDC-0941 is dissolved in DMSO and added to 20 mM Tris-HCl (pH 7.5) containing 200 μg yttrium silicate (Ysi) polylysine SPA beads, 4 mM MgCl₂, 1 mM dithiothreitol (DTT), 1 μM ATP, 0.125 μCi [γ-³³P]-ATP, and 4% (v/v) DMSO in a total volume of 50 μL. The recombinant GST-fusion of PI3Kα (5 ng), PI3Kβ (5 ng), PI3Kδ (5 ng), or PI3Kγ (5 ng) is added to the assay mixture to initiate the kinase reaction. After incubation for 1 hour at room temperature, the kinase reaction is terminated with 150 μL PBS. The mixture is then centrifuged for 2 minutes at 2000 rpm and read using a Wallac Microbeta counter. The reported IC50 values are calculated using a sigmoidal, dose-response curve fit in MDL Assay Explorer.
Cell Research: ^[2]	+ Expand Cell lines: SKBR-3, BT474-M1, AU-565, HCC-1419, ZR75-30, KPL-4, JIMT-1, BT474-EEI, HCC-1954, MCF-7, CALU-3, SKOV-3, and MKN-7 cells Concentrations: Dissolved in DMSO, final concentrations ~10 μM Incubation Time: 48 and 72 hours Method: Cells are exposed to various concentrations of GDC-0941 for 48, and 72 hours. Proliferation/viability of cells is detected by using the CellTiter-Glo Luminescent Cell Viability Assay. The pAkt (Ser473), cleaved caspase-3, and cleaved PARP are analyzed by western blot. The Caspase-Glo 3/7 assay and the Cell Death Detection ELISA^plus assay are used to detect caspase 3/7 activity, and apoptosis, respectively. (Only for Reference)
Animal Research: ^[2]	+ Expand Animal Models: NCR nude mice implanted with MDA-MB-361.1 cells, and SCID, C.B-17/IcrHsd-Prkdc^scid mice implanted subcutaneously with BT474-M1 cells Formulation: Dissolved in 10% DMSO, 5% Tween 20, 85% water Dosages: ~150 mg/kg/day Administration: Oral gavage (Only for Reference)

References

+ Expand

Solubility (25°C)

In vitro	DMSO	44 mg/mL (85.66 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+30% PEG 300+5% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Pictilisib (GDC-0941) SDF

Molecular Weight	513.64
Formula	C₂₃H₂₇N₇O₃S₂
CAS No.	957054-30-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	RG7321

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT02092831	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	April 2014	Phase 1
NCT01740336	Completed	Drug: GDC-0941\|Drug: Placebo\|Drug: Paclitaxel	Breast Cancer	Genentech Inc.	February 6 2013	Phase 2
NCT01474668	Completed	Drug: GDC-0941	Healthy Volunteer	Genentech Inc.	October 2011	Phase 1
NCT01240226	Completed	Drug: GDC-0941\|Drug: ketoconazole	Healthy Volunteer	Genentech Inc.	November 2010	Phase 1
NCT00999128	Completed	Drug: GDC-0941\|Drug: rabeprazole	Healthy Volunteers	Genentech Inc.	October 26 2009	Phase 1
NCT00975182	Completed	Drug: GDC-0941\|Drug: erlotinib HCl	Non-Squamous Non-Small Cell Lung Cancer Solid Cancers	Genentech Inc.	September 2009	Phase 1

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Pan PI3K Inhibitor

LY294002 : Pan-PI3Kα/δ/β inhibitor, IC50=0.5 μM/0.57 μM/0.97 μM.
Most Potent PI3K Inhibitor

Duvelisib (IPI-145, INK1197) : PI3K δ, IC50=1 nM.
FDA-approved PI3K Inhibitor

CAL-101 (Idelalisib, GS-1101) : Approved by FDA for Relapsed Chronic Lymphocytic Leukemia, Follicular Lymphoma and Small Lymphocytic Lymphoma.
Newest PI3K Inhibitor

GSK2636771 : Potent, orally bioavailable, PI3Kβ-selective inhibitor, sensitive to PTEN null cell lines.

Related PI3K Products

Taselisib (GDC 0032) ^New

Taselisib (GDC 0032) is a potent, next-generation β isoform-sparing PI3K inhibitor targeting PI3Kα/δ/γ with K_i of 0.29 nM/0.12 nM/0.97nM, >10 fold selective over PI3Kβ.

Features:A beta isoform-sparing PI3K inhibitor.
Pilaralisib (XL147) ^New

Pilaralisib (XL147) is a selective and reversible class I PI3K inhibitor for PI3Kα/δ/γ with IC50 of 39 nM/36 nM/23 nM in cell-free assays, less potent to PI3Kβ. Phase 1/2.
GNE-317 ^New

GNE-317 is a potent, brain-penetrant PI3K inhibitor.
LY294002

LY294002 is the first synthetic molecule known to inhibit PI3Kα/δ/β with IC50 of 0.5 μM/0.57 μM/0.97 μM, respectively; more stable in solution than Wortmannin, and also blocks autophagosome formation. It not only binds to class I PI3Ks and other PI3K-related kinases, but also to novel targets seemingly unrelated to the PI3K family.
3-Methyladenine (3-MA)

3-Methyladenine (3-MA) is a selective PI3K inhibitor for Vps34 and PI3Kγ with IC50 of 25 μM and 60 μM in HeLa cells; blocks class I PI3K consistently, whereas suppression of class III PI3K is transient, and also blocks autophagosome formation. Solutions of 3-MA are best fresh-prepared by heating.
Idelalisib (CAL-101, GS-1101)

Idelalisib (CAL-101, GS-1101) is a selective p110δ inhibitor with IC50 of 2.5 nM in cell-free assays; shown to have 40- to 300-fold greater selectivity for p110δ than p110α/β/γ, and 400- to 4000-fold more selectivity to p110δ than C2β, hVPS34, DNA-PK and mTOR.
Wortmannin

Wortmannin is the first described PI3K inhibitor with IC50 of 3 nM in a cell-free assay, with little selectivity within the PI3K family. Also blocks autophagosome formation and potently inhibits DNA-PK/ATM with IC50 of 16 nM and 150 nM in cell-free assays.
Dactolisib (BEZ235, NVP-BEZ235)

Dactolisib (BEZ235, NVP-BEZ235) is a dual ATP-competitive PI3K and mTOR inhibitor for p110α/γ/δ/β and mTOR(p70S6K) with IC50 of 4 nM /5 nM /7 nM /75 nM /6 nM in cell-free assays, respectively. Inhibits ATR with IC50 of 21 nM in 3T3^TopBP1-ER cell.
Buparlisib (BKM120, NVP-BKM120)

Buparlisib (BKM120, NVP-BKM120) is a selective PI3K inhibitor of p110α/β/δ/γ with IC50 of 52 nM/166 nM/116 nM/262 nM in cell-free assays, respectively. Reduced potency against VPS34, mTOR, DNAPK, with little activity to PI4Kβ. Phase 2.
Alpelisib (BYL719)

Alpelisib (BYL719) is a potent and selective PI3Kα inhibitor with IC50 of 5 nM in a cell-free assay, and minimal effect on PI3Kβ/γ/δ. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 114 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Choose Your Country or Region

By Signaling Pathways

By product type

Pictilisib (GDC-0941)

Cited by 114 Publications

Purity & Quality Control

Choose Selective PI3K Inhibitors

Biological Activity

Protocol

References

Solubility (25°C)

Chemical Information Download Pictilisib (GDC-0941) SDF

Bio Calculators

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Dilution Calculator

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

The Serial Dilution Calculator Equation

Serial Dilutions

Computed Result

Molecular Weight Calculator

Total Molecular Weight: g/mol

Instructions to calculate molar mass (molecular weight) of a chemical compound:

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on )

Tech Support

PI3K Signaling Pathway Map

PI3K Inhibitors with Unique Features

Related PI3K Products

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)